Enovis
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of h...
Latest News
4 days ago · globenewswire.com
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in LondonDallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT (6:30 a.m. ET).
10 days ago · marketbeat.com
What Enovis (ENOV) Said on Its Q3 Earnings CallEnovis NYSE: ENOV reported third-quarter sales of $559 million and raised its full-year adjusted earnings outlook, as growth in its reconstructive business and improved cash generation helped offset what executives described as a volatile market for medical procedures.
11 days ago · seekingalpha.com
Enovis Corporation (ENOV) Q3 2026 Earnings Call TranscriptEnovis Corporation ( ENOV ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Ross Osborn - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vikramjeet Chopra - BMO Capital Markets Equity Research Steven Lichtman - William Blair & Company L.L.C.
12 days ago · zacks.com
Enovis (ENOV) Q3 Earnings and Revenues Beat EstimatesEnovis (ENOV) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.
12 days ago · globenewswire.com
ENOVIS Announces Third Quarter 2026 ResultsDallas, TX, Nov. 05, 2026 (GLOBE NEWSWIRE) -- - Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
1 month ago · globenewswire.com
Enovis to Host Third Quarter 2026 Results Conference Call on November 5thDallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.
2 months ago · prnewswire.com
Enovis becomes first multi-registry industry sponsor of AAOS Registry ProgramCompany expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.
2 months ago · zacks.com
What Makes Enovis (ENOV) a New Buy StockEnovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 months ago · zacks.com
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerEnovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
3 months ago · zacks.com
Enovis Boosts Surgical Robotics Portfolio With eCential AcquisitionENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ENOV